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Abstract

THE EFFECTS OF PREGNANCY ON SYSTEMIC
LUPUS ERYTHEMATOSUS

by Julia Christenssn

The safety of pregnartcy for the woman with systemic lupus erythematosus (SLE) has long been studieci. Controversy exists about the
occurrence of exacerbations during pregnancy and the effect these exacer

bations will have on the basic disease process. The purpose of this

study was to investigate the effect pregnancy would have in precipitating
exacerbation of disease activity. The investigation was carried out by
Gomparing two matched groups of women with SLE, one group pregnant and
the other group nonpregnant. The difference in occurrence of exacerba-

tion among the three trimesters of pregnancy and the prepregnancy, preg
nancy, and postpartum periods was also studied.

This nonexperimental descriptive case study used medical records

of six pregnant (the study group) and six nonpregnant (the control group)
women with SLE. The criteria for the sample selection was designed to
eliminate as many extraneous variables as possible. All patients who
met the sample cri teria for the study group were included in the study.
The records were then surveyed for all who met the cri teri a for the con

trol group. The control group was then matched to the study group
according to grade of disease activity; presence or absence of cortI-

costeroid administration; age, plus or minus five years. Each medical

record was reviewed for demographic data, past and present history of
disease activity, and medications being taken.

When the six pregnant woraen with SLE were compared with the six
nonpregnant SLE women, the occurrence of exacerbations was higher in the

nonpregnant group. This may point to the fact that pregnancy does not
always precipitate an exacerbation of disease activity. But because of
the limitations of uhcontrolled variables, sample size, difficulty in
matching disease activity and length of time since origihal diagnosis,
ahd imbalanoe in length of hospital records, generalization of this find
ing is impossible.

From the eight pregnancies reported, during pregnancy the only
two exacerbations occurred during the third trimester, within six weeks

of delivery. It was also found that of the prepregnancy, pregnancy, and
postpartum periods, two exacerbations occurred during postpartum, two

during pregnancy, and none during prepregnancy. These data suggest that
if pregnancy were undertaken by the women with SLE the risk of exacerba

tion might be greatest during the third trimester and postpartum. The
sample size of the present study, however, is too small to make such a
general ization.
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Chapter 1

THE PROBLEM

Introduction

A Caucasian female, age 21, became pregnant for the second tifhe.

The first child had been del ivered without CGmpi ication and the second
pregnancy was uneventful until approximately 35 weeks gestation, when

fever, prOteinuria, and acute pulmonary edema developed^

While in the

coronary care unit on a ventilator, the mother delivered her second child.

Five days postpartura a diagnosis of systemic lupus erythematosus (SLE)

was made and steroid therapy was initiated. Her condition rapidly im-^
proved and she was discharged one week later on 60 mg of prednisone daily.
A week later, at a clinic visit, her condition was so much improved that
prednisone therapy was reduced to 15 mg daily. Two days later she was

readmitted with pulmonary edema and gram-negative septicemia. She expired
that day.

De1i neati on of the Problem

Systemic 1upus erythematosus is a chronic inflammatory disease of

unknown origin with depos i t ion of immune complexes in several organs

(lurier, Argyros, Urman, Warren, and Rothfield, 1977, p. i78). The
clinical manifestations vary widely as does the course of the disease.

In most cases the disease pursues a chronic, irregular course marked by
exacerbations and remiss ions. The relatively benign nature of the
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disease is demonstrated by a 10-year survival rate exceeding 90 percent
(Fessell, 197^, p. 1027).
It was not until 1971, when the American Rheumatic Association

defined preliminary criteria for diagnosis of SLE, that there was any
uniformity in diagnosis. With the discovery of the lupus erythematosus

cell in 19^8 and of other serological data, early recognition and treat
ment became possible. These recent djscoveries coupled with a heightened
awareness of diagnosis might partially explain the increased incidence of

1:700 in women 15 to 65 years old and 1 :2^5 in black women 15 to 65 years
old. Clearly SLE has replaced acute rheumatic fever as the gravest
rheumatic disease (Fessell, 197^, p. 1030).
Systemic lupus erythematosus occurs four times more often in women

than it does in men (Rodnan, 1973, p. 39). Ohset most frequently occurs

during the period of menarche to the raenopause, with peak onset during
the second decade (Estes and Larson, I965, p. 308). Prevalence is there
fore greatest for women during the reproductive years.
A review of the literature on the effects of pregnancy on SLE

yields contradictory findings. Some investigators say exacerbations
occur equally during both halves of pregnancy (McGee and Makowski, 1970,

p. 1010), others that they occur.in the second half (Zurier, and Others,
1978, p. 179), and still others that they occur during the first part of
pregnancy (Friedman and Rutherford, 1956, p. 606). The majority of
articles show exacerbation the rule during postpartum, although in two
studies postpartum exacerbation was minimal or nonexistent (McGee and

Makowski, 1978; Fraga, Mintz, Orozco, and Orozco, 197^). This reduction
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in postpartum exacerbation has been attributed to the use of corti-

costeroids throughout pregnancy and/or high dose regimens prior to the
onset of labor.

Since SLE occurs most frequently in women during the reproductive

years, it would follow that questions concerning safety of pregnancy would
frequently be asked of the nurse as the patient attempts to make decisions
about her reproductive status.

At present it is not clear what effect

pregnancy has on SLE.

If a patient with SLE under good control and without evidence of

renal disease should become pregnant could her disease become fatal?

This question surfaces on examination of the literature, where two
striking factors are reported: first, from the surveyed literature the

reported maternal mortality rates ranging from 0-AO percent, and second,
the number of women in wh ich symptoms of the disease did not become

apparent until they were pregnant or during the postpartum, 20.7 percent

according to Fraga (197A) and 33 percent according to Garsenstein (I962).
It appea rs that a seemingly qu i escent d isease process may be activated
by pregnancy.

Research Quest ions

Because of the 1 imitations of sample size and medical records
th is study was descriptive in nature and was concerned with research

questions and their answers rather than with testing hypotheses. The
three questions were as fo11ows:

1. What effect will pregnancy have in precipitating exacerbation

h

of disease activity in women With SLE when they are compared with a
similar group of nonpregnant women with the disease?
2.

Is there a difference in the occurrence of exacerbations of

SLE during the first, second, and third trimesters of pregnancy?
3.

Is there a difference in the occurrence of exacerbations

during prepregnancy, pregnancy, and the postpartum period of the SLE
patient?

Conceptual Rationale

Systemic lupus erythematosus is considered an autoimmune disease

characterized by an imbalance in the immune system. Bursa dependent (B)
I

cell activity and antibody responses are excessive. Thymus dependent (T)
cell activity or ceM-raediated immunity is depressed.

It appears that

antibody production or suppression is controlled by helper T cells or
suppressor T cells.

Loss of suppressor T cell activity has been impl i

cated as an underlying factor in pathogenesis of autoimraune disease

(Krakauer, 1977, p. 56).
During pregnancy mixing of fetal and maternal blood may occur if

placental blood vessels are torn during abortion or during late pregnancy.
But the most frequent mixing occurs with disruption of fetal placental

vessels during the third stage of labor (Willson, Beecham, and Carrington,
1975, p. A35).
It has been shown that pregnancy presents a new antigenic stimulus

to the mother in the form of incompatible paternal HLA-antigens. Lymphocytotoxic antibodies have been detected in 20 to 50 percent of pregnancies.

^ 5

depending on parity.

It is suspected that their incidence increases not

only with parity but with multiple paternity as compared to single
paternity (Harris and Lordon, 1976, p. 302).
If these statements are true then an antigenie stimulus, such as

Incompatible fetal antigens released during late pregnancy or del ivery to
an already-abnormal immune system could precipitate an exacerbation of
disease activity.

If pregnancy presents, as such, a serious threat to health

stability, patients could be informed of such risks and be given alterna
tive solutions to pregnancy.

If pregnancy is desired, careful observation

during pregnancy and postpartum could be planned with emphasis on com
pliance to a medical regimen.

,

Def i n i t ion of Terms

The following terms are defined for the purposes of this study.
Systemic Lupus Erythematosus

A person presenting serially or simultaneously any four of the

14 preliminary criteria proposed by the American Rheumatism Association.
See Appendix E for a listing of criteria.
D i sease Act i v i ty

The level of disease activity classified by the following grades:
Grade 0. No systemic symptoms; no evidence of organ involvement.
Grade 1.

One or two clinical manifestations which do not l imit

activities of daily l iving, including employment.
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Grade 2. Two or more cTinlca] roanifestat Ions Which limit the

patient In dally living. Including employment.
Grade 3. Acute Illness requiring hospitallzatlon.
Exacerbation

An Increase of disease activity by one or more grades.
Prepregiiancy

The six-week period Immediately preceding conception.
Postparturn

The six-week period after termination of pregnancy.
Abortion

Termination of pregnancy before the end of the twentieth week,
either spontaneously or therapeutleally.
Gravlda

All pregnancies prior to the case being surveyed.
False-Positive Venereal Disease
l^ssearch Laboratories (VDRL)

The presence of anticardlolipin antibodies In a patient with no
clinical or historical evidence of syphilis, and whose serum fluorescent

treponemal antibody absorption test is negative (Beeson, McDermott, and
Wyngaarden, 1979, p. SH).

Anerqy to Skin Tests

Reduced reactivity of the delayed-hypersensitivity skin testing
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to common antigens such as tuBercuHn, mumps, streptokinase, and strepto-

dornase (Beeson, and Others, 1979, p. 150).
An t i n uc 1 ea r An t i bod ies
The presence of antibodies in nuclear material at any titer. A

positive test supports the diagnosis of SLE, and a negative test is strong
evidence against the diagnosis.
Lupus Erythematosus (IE) Cell

A traumatized leukocyte that releases nucleoprotein which reacts

with an igG antibody and is later phagocytized by the remaining viable

leukocytes. LE cells are present in 75 to 90 percent of patients with

SLE (Beeson, and Others, 1979, p. 178; Rodnan, 1973, p. 46).
Complement

Circulating inactive precursor proteins which, upon activation,

mediate and amplify the inflammatory response (Beeson, and Others, 1979,

p. 135). Complement levels are low when disease activity is present in
SLE and reflect activation and fixation of complement components by cir

culating immune compiexes. Levels of C^ are often measured in hospital
laboratories, a1though total complement and C^ are preferred for follow
ing progression of disease activity (Buimash, 1978, p. 172).
Apgar

Evaluation and scoring of the five objective signs (heart rate,
respiratory effort, muscle tone, response to catheter in nostri1, and

color) at 60 seconds and again at five minutes after complete birth of
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the infant. A total of 10 indicates an infant In the best possible con

dition (Vaughan, McKay, and Nelson, 1975, p. 334).
Limitations

Limitations of the study were as follows:

1. Rating errors by the data researcher with either overrating
or underrat ing i nformat I on.
2.

Researcher bias.

3.

Post-hoc error.

4. Nonrandom sampl ing.
5.

Small sample size.

6. Unidentified extraneous variables.
7.

Incomplete or inaccurate medical reGOrds.

Assumptions

The following assumptions were considered true for the purposes
of this study. Some of these assumptions are currently controversial,
and evidence may exist that they are or are not true.

1. The possibility exists that pregnancy can precipitate the

onset of initial clinical manifestations of SLE (Fraga, Mintz, Orozco,
and Orozco, 197^, p. 179).

2. Administration of corticosteroids decreases the percentage

of exacerbations during pregnancy and the postpartum {Zurier, and Others,
1978, p. 179).

3. Incompatible fetal antigens released late in pregnancy or
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delivery provide an antigenic stimulus for exacerbation of disease
activity.

k. Surveyed medical records are well documented and rel iable.
Qrgani zat ion of Rema inder of the Study

Chapter 1 is a general introduction to the study. Chapter 2

reviews the 1 iterature and related studies.

Chapter 3 presents the re

search method and the data collection procedures which were used. Chap

ter k presents and analyzes the data. Chapter 5 gives conclusions and
recommendations.

Chapter 2

REVIEW OF LITERATURE

The reviewed literature has been classified under two general

topics and will be presented in the following order; SLE and pregnancy,

with emphasis on exacerbations; and precipitating facto''s of exacerba
tion.

Systemic Lupus Erytheroatosus
and Pregnancy

The earliest references to lupus and pregnancy appeared in the
literature In the 1950's. Donaldson first reported eight cases in 1952
and Friedman and Rutherford critically reviewed 29 cases In 1956.

Between

1952 and 1971 a large number of studies were written before uniform cri-

t^ia for diagnosis were proposed.

Consequently, it is difficult to sum

marize and generalIze findings because the studies have not separated
systemi c disease from discoid, and ben i gn d i sease from either lupus
nephritis or central nervous system manifestations.

It is of interest to

note that the majority of studies have been written by obstetricIans, and

criteria for differentiation of 1upus are not mentioned. Currently, even
with the establ ishment of un i form cr i ter ia, the complexity of the disease
i tse1f makes genera1i zatIons di ffIcult.

Several studies are frequently cited because of their large samp 1e

sizes. Fraga reports 79 patients (Fraga, and Others, 197^, p. 294) and

Friedman reports 80 patients (Friedman and Rutherford, 1956, p. 603).
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The large sample size was used for the calculation of fertility potential,
not for the course of SLE during pregnancy,

in considering lupus and

pregnancy, the researchers studied either a subgroup from the large sample

or a small independent group.

The sample sizes ranged from five to 36

patients except for 13^ reported by Donaldson and deAlvarez (1962, p. 1%6A).
Another striking limitation of the eight studies reviewed is the

absehce of control groups in all but two studies.

Fraga (197^, p. 29^)

utilized a control group, but it consisted of a comparable group of healthy

females.

This type of control may have been helpful in comparing fertility

and fetal wastage rates, but for studying the course of lupus during preg
nancy it lacked the type of relationship necessary for comparison.

Garsen-

stein utilized a 32-week period before conception and nine to ^0 weeks

after delivery as Gontrol periods for each pregnancy (Garsenstein, Pollack,

and Kark, 1962, p. 166).
In reference to the effects of pregnancy on SLE^, the reviewed

literature identified three important points.

First, the high rate of

initial onset of SLE occurred during pregnancy or postpahtura periods.

Estes and Larson (1965, p. 309) reported 17 percent with initial onset,
Fraga (197'>, p. 295) 20.7 percent, Garsenstein 33 percent (1962, p. I66).
In Friedman's 29 patients with 24 pregnancies there were 13 cases of

initial onset (Friedman and Rutherford, 1956, p. 606). If, pregnancy pre
cipitates onset of initial disease activity, the potential for exacerba
tion during pregnancy may be equally in force.

Second, the reported occurrence of exacerbation during pregnancy
is contradictory, a 1 though recognition of postpartum exacerbation is
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unanimously agreed upon.

In Friedman's report of 29 patients, of which

six had discoid lupus, there were 18 exacerbations during pregnancy, 10

during the first trimester, seven during the second, and one during the
third trimester. There were 18 exacerbations postpartura plus eight cases

of initial onset of disease activity. The number of remissions nearly
equaled the number of exaGerbations during pregnancy. From these find

ings he concluded that pregnancy did not alter the basic course of lupus
and that those patients whose disease progressed during pregnancy would
have experienced a progression despite the pregnancy. This may seem a

logical conclusion, but the absence of a contro1 group makes such state
ments inconclusive (Friedman and Rutherford, 1956).
Donaldson and deAlvarez's study.concluded with results similar to

Friedman's. In this sample of 105 pat ients (excluding those with discoid

lupus) with 153 pregnancies, the majority had no change in their disease
status nor an improvement. Exacerbation occurred in 2h cases during
pregnancy.

During the postpartura period 59 cases showed no change in

disease activity, 21 cases improved, and kB has exacerbations. The re

searchers felt that pregnancy does not aggravate the basic disease process
and that the high rate of postpartura exacerbation is related to withdrawal

of 17~hydroxycorticosteroids elaborated as pregnancy advances (Dona 1dson

and deAlvarez, 1962). When one examines the study design a question arises
about generalizing these findings. Of the 13^ patients, including those
with diSCOid 1upus, it is noted that for 112 the data were obtained from a

questionnaire sent to obstetricians and gynecologists. The seven-question
questionnaire asked general questions relating to pregnancy and disease
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activity without offering specific objective criteria.

Data from medical

records were obtained from only 22 patients.
Estes and Larson found results similar to those of the above

studies. A retrospective study of 79 pregnancies in 36 patients concluded
that pregnancy does not alter the course of SLE in the majority of cases.
Exacerbations were associated with 18 pregnancies, none in the first tri

mester, four in the second, three in the third, and 11 in the postpartum
period.

They concluded that pregnanGy may be undertaken In the absence

of renal disease or hypertension without undue risk to the patient. They
recommend close observation into the third month postpartum in view of
the tendenGy for postpartum exacerbation (Estes and Larson, 1965).

Garsenstein and others studied 33 pregnancies in 21 patients.

For

analysis pregnancy was divided into two 20-week periods and a third period
consisting of the first eight weeks postpartum. Two control periods con
sisted of 32 weeks prior to conception and from nine to AO weeks after
delivery.

From these data, the number of exacerbations and remiss ions

per 100 weeks of risk was calculated.

During the first 20 weeks the risk

of exacerbation was three times as great as in the control periods.

In

the second 20 weeks the risk decreased to 1.7 times the control, but most

strikingly it increased to seven during the postpartum period. S ixteen

patients were treated with prednisone throughout or for part of the preg
nancy, while in 17 cases no prednisone was given. Of the group that

received no prednisone 16 exacerbations occurred during pregnancy and 11
in the first eight weeks postpartum.

In the 16 treated cases only eight

exacerbations occurred during pregnancy and five postpartum.

From these
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data the authors concluded that pregnancy inGreases the chances of
exaGerbation of SLE, particularly during the first half of pregnancy and
first eight weeks postpartum.

These results are similar to those of

Friedman and Rutherford. The latter concluded that the postpartum de
crease in the serum level of 17"hydroxycorticosteroids occurs too early
after pregnancy to be the sole explanation for the increased number of
exacerbations four to eight weeks after delivery.

It was also concluded

that prednisone does decrease the rate of exacerbation (Garsenstein, and
Others, 1962).

McGee and Makowski studied 11 pregnancies in seven patients to

evaluate the effectiveness of therapeutic programs in the management of
SLE during pregnancy. Corticosteroids were used to control symptoms
during pregnancy.

In addition, all patients treated with corticosteroids

during pregnancy received a high dose of oral and intravenous steroids

at the onset of labor.

Intravenous therapy was discontinued the first

postpartum day, but the oral corticosteroid was continued until three

weeks postpartura and then gradually tapered in accord with clinical and

laboratory data. Five of the 11 pregnancies had no change in symptoms.
Exacerbations occurred in equal numbers during the first and second halves

of pregnancy.

No maternal deaths and no postpartum exacerbations were

encountered. The authors felt that these data suggest that high-dose
corticosteroid therapy during the intrapartum period is effective in pre
venting postpartum exacerbation (McQee and Makowski, 1970).

Similar reductions in postpartum exacerbations were reported by

Fraga and others (197^) and Zurier and others (1977). A retrospective
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study of 42 pregnancies in 20 patients by Fraga showed no exacerbations
during the first trimester, three during the second, two during the third,
and two postpartum, for a 13.2 percent exacerbation rate. Thirty-three
of the pregnancies were treated with corticosteroids and nine were not.

in the nihe who were not treated, two maternal deaths occurred.
the patients improved or had a remission.

None of

The authors' recommendation is

that pregnancy be permitted during a clinical remission or well-controlled

disease and that steroid therapy be utilized to reduce exacerbations

(Fraga, and Others, 1974).
Zurier and others retrospectively surveyed 27 pregnancies in 13

patients and reported six exacerbations during the second half of preg
nancy and three during the postpartum period, for an 11.1 percent exacer
bation rate.

Nineteen of the 27 pregnancies were treated with various

doses of prednisone (5-60 mg/day) during pregnancy and 16 were treated
throughout the entire course of pregnancy (Zurier, and Others, 1978).
From these studies come contradictory conclusions about the occurrence

of exacerbations of SL£ during pregnancy, although there appears to be a
definite increase in postpartum exacerbation.
The third point iliuminated in a review of the literature is the

fact that despite the number of exacerbations, maternal mortal ity rates
are not increased except for patients with lupus nephritis.

In an

attempt to further differentiate the effects of pregnancy and lupus

nephritis. Bear studied six pregnancies in five patients with quiescent

lupus nephritis. Proteinuria increased during five of the six cases,
with three progressing to heavy proteinuria without response to prednisone.
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Two patients with heavy protelnurla died within two years of del ivery
despite prednisone and azathioprine therapy. The one patient with no

change in proteinuria received prednisone throughout pregnancy, 15 mg/
day. The author concluded that pregnancy deals a further insult to renal

integrity with heavy and persistent proteinuria (Bear, 1976). Similarly,
Estes found a progression of renal disease during pregnancy in all pa
tients with lupus nephritis. Of 10 pregnancies associated with renal

disease, five patients reverted to a prepregnancy state of renal disease,
three had a stabilization in renal disease, and two progressed to death
within one year of delivery (Estes and Larson, I965, p. 316). McGee and
Makowski also noted a decrease in renal function despite corticosteroids

during pregnancy, but all cases improved after eight weeks postpartum

(1970, p. 1012). In Garsenstein's study there were four maternal deaths,
19 percent. All four patients had lupus glomerulonephritis. None were
treated with corticosteroids. The authors compared the number of deaths

in both the pregnant and the nonpregnant patients with lupus nephritis
and found no difference (Garsenstein, and Others, 1962, p. 168). In the
studies reviewed, the maternal mortality rate ranged from 0-40 percent
with the majority of deaths from progression of 1upus nephritis.
Preci p i ta ting Factors of
Exacerbat i on

The factors precipitating exacerbat ion of SLE dur ing pregnancy
are unknown. Possible explanations could include the rapid decl ine in
cortisol levels following del ivery and/or a hypersensitivity immune
response stimulated by paternal fetal antigens.
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In the literature reviewed in the previous section two references

discussed the relationship of exacerbation to 17-hydroxycorticosteroids
secreted during pregnancy.

Donaldson and deAlvarez felt that the loss of

the suppressive effects of the corticolds postpartutn could precipitate

the high incidence of postpartum and postabortal exacerbation (1962, p.

1%68).

Garsenstein and others felt that the 1ack of 17~hydroxycorticoste-

roids occurred too soon after delivery to account for the incidence of

exacerbation seen four to eight weeks after del ivery (1962, p. 169).

Total plasma cortisol and cortisol-binding globulin levels in
crease during pregnancy.

Under normal conditions 90 percent of serum

cortisol is bound to a specific binding globulin, namely, the corti-

costeroid binding globulin (Brien and Dalrymple, 1976, p. 361).

It is

the nonprotein bound or free cortisol that is the metabolically-active
form of cortisol.

Historically controversy has existed about the levels

of plasma bound and free cortisol during pregnancy.

The recent l itera

ture reviewed all supported the fact that nonprotein-bound cortisol

increases during pregnancy (Doe, Dickinson, Zinneman, and Seal, 1969, p.

760; Galvao-Teles and Burke, 1973, p. 738; Brien and Dalrymple, 1976, p.
362).

Doe and others noted that a cortisol-1 ike aminoaciduria was

present in pregnancy and felt that clinical symptoms such as purpl ish
striae, easy bru is i ng, hypertens i on and flu id retent ion were cons i stent

with a mild cushingoid state (1969, p. 76^). Brien and Dalrymple,
measuring cortisol levels in 23 pregnant women at four-week intervals

during pregnancy and six weeks postpartum, found that total plasma
cortisol and free cortisol were significantly elevated by 12 to 15 weeks
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of gestation and Gontinued to fise throughout pregnancy.

Bound cortlsol

was significantly elevated by 12 to 15 weeks, peaked at 20 to 23 weeks,
and fell slowly thereafter until terra (1976, pp. 362-363).

None of the

studies raeasured cortlsol levels on a daily basis postpartura to deterraine the fall of plasraa cortlsol.

Gerazell measured the level of 17-

hydroxyGorticosterolds six days after delivery and found them within

norraa1 range (1953, p. 901)' Brien and Dalrymple raeasured cortlsol
levels at six weeks postpartura and found all pararaeters at nonpregnant

levels (1976, p. 363). The fall of plasraa cortlsol postpartura with a
resultant loss of anti-inflararaatory and iraraunosuppressive effects may
contribute to exacerbation.

Lack of rejection of a fetus which possesses both raaternal and

paterna1 genes is an enigma to those studying the immunology of pregnancy.
The fact that raaternal sensitization does occur in response to fetal
tantigens can be demonstrated by various laboratory methods. Terasaki,

Mickey, Yamazaki, and Vredevoe demonstrated raaternaI sensitization by
measuring lymphocytotoxic antibodies. They found 16.7 percent of women
after one pregnancy developed cytotoxic antibodies, 23.6 percent after
two, 36 percent after three, and ^4,5 percent after four. Around the

fourth pregnant a plateau was reached (1970, pp. 539-440). In studying

85 primiparous mothers Thillkainen, Schroder, and dele Chapelle found
22 percent developed cytotoxic antibodies to paternally derived antigens
(1974, p. 356).
Another laboratory method uti1ized to evaluate the eel 1-raediated

imraunological response to fetal antigens was the assay of the macrophage
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migration inhibitory factor, which is elaborated from sensitized lyrapho-*
cytes.

The serum of five of 10 pregnant patients with differing parity

produced a migration inhibition factor when it was incubated in the

presence of their infants' lymphocytes.

All five of the mothers whose

lymphoGytes were Sensitized to those of their infants had been pregnant

three or more times (Rocklin, Zuckerman, Alpert, and David, 1973, pp.

130-'131). in a si mi lar study of five mothers with three or more preg
nancies, lymphocytes produced migration inhibition factor in three of

five mothers in the third trimester and five of five mothers in the postpartura.

The migration inhibition factor was produced only in the presence

of homologous pregnant plasma; when autologous plasma was util ized no
migration inhibition factor was produced. This suggests that maternal
sensitivity to paternal antigens is blocked by some factor in autologous

maternai plasma (Pence, Petty, and Rocklin, 1975, p. 526).
These studies support the fact that maternal xsensitization to

paternal fetal antigens does occur.

Since the presence of antibodies

increases with parity one wonders if maximum antigenic stimulus occurs
immediately prior to or during 1abor when fetal and maternal blood mix

as separation of piacenta from uterus occurs (Willson, and Others, 1975,

p. ^35).
Systemic 1upus erythematosus is a disease in which the regulation
of immune response is abnormal.

An ant igenie stimulus In the form of

paternal fetal antigens delivered to the maternal circulation during labor
could precipitate exacerbation of disease activity.

Chapter 3

METHODOLOGY

The nonexperiraental case study method .was used in this study.
Data were obtaihed from the medical records of 12 patients from two hos
pitals.

The records were surveyed between May, 1979, and June, 1979.
Select ion of Sample

The target population for the study included SLE women hospital
ized for pregnancy, where pregnancy occurred after the initial diagnosis
of SLE, and/or evaluation of disease activity.

Medical records from one

500-bed university medical center and one 250-bed county hospital were
reviewed from the years 1968 to 1978.

Criteria for Selection of

Patients were included in the study if they met the fo11owing
general criteria:
1.

Female.

2.

Age 16 through k5.

3.

SLE diagnosed according to American Rheumatism Association

cri teria (see Appendix E).
Patients in Group A, the study group, met the following addi

tional cri teria (at 1 east four pat ients requi red):
1.

Documented history of pregnancy past 16 weeks gestation.

2.

Diagnosis of SLE prior to pregnancy.
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Patients in Group B, the control group, met the additional

criteria of no history of pregnancy (at least four patients required).
AM patients who met the sample criteria for Group A were in
cluded in the study sample.

The records were then surveyed for all who

met the criteria for Group B.

Group B was then matched to Group A

according to grade of disease activity, presence or absence of corticosteroid administration, age plus or minus five years.

The time period

used for comparison was a period of relative disease stabil ity prior to

the surveyed pregnancy for Group A and prior to exacerbation in Group B.

Uncontrolled Variables

Variables that may have existed and affected the study include
the following:

1.

Incorrect diagnosis of SLE, despite utilization of diagnostic

criteria.

2.

Incorrect or incomplete medical records.

3. Patient noncompl iance to medical regime.
k.

illnesses other than those associated with SLE.

5.

Additional medical/social history pertinent to the case.

6.

Length of medical record available.

Collection of Data

After sample selection each medical record was reviewed by means

of a data extraction checklist (see Appendix F).

In each case the entire

medical record was reviewed for pertinent data, often far in excess of

that required from the checkl ist.

Data were reviewed by a single researcher.

22

Data-Gathering Tool

'

information collected by the data-gathering tool consisted of
jraphic data; past history of disease activity as to American Rheuma

tism Association criteria; prepregnancy, pregnancy, and postpartum periods;
medication being taken.

Prior to uti1ization of this tool, a pretest was performed. When
the information obtained by the researcher was compared with that of
another person the results were similar.

In using the tool it was felt

the information obtained was the minimum, basic information required.
S ta t i st i ca1 Ana1ys i s

The data col 1ected were examined in a descriptive approach.

This method of analysis was felt to be most appropriate for this study
because of the severe limitation of sample size, sole utilization of
medical records for data collection, the retrospective nature of the
study, and the severe 1 imitations of the uncontrolled variables.

Limi tat ions

In addition to the limitations described in Chapter 1 the fol

lowing limitations became apparent as the study progressed:
1.

No uniform point was set for beginning data collection in

relation to disease process, diagnosis, or delivery.
2. The length of time over which survey data were available did
not compare between groups, one week shortest time and six years, four
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months longest.

In al1 but one of the pregnant group only months were

surveyed. Thus, comparisons between the group of patients who were

pregnant and those who had never been pregnant were not possible although
originally intended.

3• The two groups were not adequately matched. This may have

been due in part to the vague criteria for grading disease activity used
in this study.

Chapter ^

PRESENTATION OF FINDINGS

The major purpose of this study was to discover whether or not

pregnancy precipitated exacerbation of disease activity in six women with
diagnosed SUE.

The two subsidiary purposes were to find out (1) whether

there is a difference in the occurrence of exacerbations of SLE during
the first, second, and third trimesters of pregnancy and (2) whether there

is a difference in the occurrence of exacerbations during prepregnancy,
pregnancy, and the postpartura periods of the SLE patient,

Descri ptive Data

Demogra ph i c Da ta

The sample of 12 women with SLE consisted of six women who had

never been pregnant and six who became pregnant between the time the
original diagnosis was made and the time of the survey.

The racial

characteristics were similar in each group; the total group consisted of
four Gaucasians, six Mexican-Americans, and two Blacks, Ages ranged from

l8 through 29* The two groups were matched on age, plus or minus five
years; presence or absence of corticosteroid administration; grade of

disease activity. The period prior to the surveyed pregnancy for Group A
and prior to exacerbation for Group 8 was used for comparison. Because
of the multiple exacerbations in all but two cases in Group B, the first
stable time after the first recorded exacerbation was used for reference.

Table 1 compares these data.
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Case Studies of Pregnant Group

In the sample of six pregnant women there was a total of eight
pregnancies.

Table 2 summarizes the reproductive history prior to the

surveyed pregnancies.

Case A.

At age 16, this Caucasian fema1e first had symptoms of

SLE, which included migratGry arthralgias, afternoon and evening fevers,

bilateral subcostal pain, and blotchy skin eruptions over the cheek bones.
The ANA and LE cell tests were positive, each on three occasions.

The

sedimentation rate was elevated but the creatinine clearance and VDRL were

normal. Symptoms were controlled with 20 to hO mg of prednisone daily,

although symptoms recurred with attempts to reduce the dosage.
One fTOnth after this initial diagnosis she was rehospital ized for

fever, pleuritic chest pain, and blood cultures positive for alpha strep
tococcus. Treatment included antibiotics, Imuran 75 mg daily and large

doses of prednisone from 60 to 120 mg daily. After one month she was

discharged on kS rag of prednisone and 75 mg of Imuran daily. She con
tinued to take these med i cat ions over the next two and one-half years,

although the prednisone was s1owly reduced despite episodic arthralgias,
pleuri t ic pain, and myalgias.

Dur ing th is t ime she married and became

pregnant for the first time, despite an intrauterine device.

She chose

to continue the pregnancy regardless of medical advice, and the imuran
was subsequently reduced at five months and discontinued at seven months.

At 3^ and 36 weeks gestation she went into labor prematurely and delivered
a male ch iId weighing 5 pounds, 5 ounces wi th no anomalies, but an apgar
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of 1/7.

The child died three days after hirth.

was unknown.

The exact cause of death

No postmortem examination results were recorded on the

chart.

No symptoms of exaGerbation were noted during the pregnancy,
delivery, or postpartum except for stiffness of joints, fever, and
malaise several days prior to del I very.

While in labor and the imme

diate postpartum period she received 100 mg of Solu-cortef, two 100 mg
doses of cortisone acetate, and two 20 mg doses of prednisone.

One week following discharge the prednisone was tapered off with
no f1 are of symptoms.

Five months after delivery she was working part-

time, asymptomatic, and off all medication, and ANA and LE cell tests

were negative.

'

At age 20, during this asymptorrtatic period, she became pregnant
for the second time. She remained asymptomatic through the pregnancy
and delivered a ful1-term male child weighing 7 pounds» 8 ounces, with
an apgar of 9/10; no anomal ies were noted.

No medication was given dur

ing labor or postpartum, and she remained symptom free.

She became pregnant for the third time at age 22. During preg
nancy and delivery no manifestations of disease activity were noted, and

she delivered a ful1-term fema1e weighing 7 pounds, 11 ounces with an

apgar of 9/10. Six weeks pcstpartum she noted the onset of joint stiff
ness, which was successful 1y control 1ed with aspirin.

No other cl inical

manifestations of disease activity were noted at this time; her sedimen-

tation rate was normal, the ANA was positive. Three months later joint
pains continued, but no other symptoms occurred.
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Case B.
as having SLE.

At age 16, this Hexican-American female was diagnosed
Clinical manifestations included hemolytic anemia, Coombs

positive, a negative LE cell test, a false-positive VDRL and a positive
ANA, arthralgias.
time.

Eight months later she became pregnant for the first

Hemolytic anemia persisted during pregnancy, for which she re

ceived 10 mg of prednlsone daily until the week before delivery, when it

was increased to 15 mg because of a drop in hemoglobin.

During the 1 ast

trimester she had 1+ to 2+ edema, a trace of albumin in the urine a week

prior to delivery, and a normal blood pressure.

a grand mal seizure.

While in labor she had

Her blood pressure was 148/100 and there was a trace

of urine protein and little edema.

It was questioned whether the seizure

was related to toxemia of pregnancy or to SLE.

Treatment included mag

nesium sulfate, Di1 ant in, Aldomet, phenobarbitai, and high dose cort1costeroids:

one dose of TOO mg of Solu-eortef, two doses of 50 mg

Depo-medrol, and 20 to 40 mg of prednisone daily. Prior to del ivery she
also developed gross hematuria with urinalysis negative for bacteria.
Wi th in ten days the red blood cell count in the urine dropped from 250 to

50 and then to 3 prior to discharge.

Areas of erythema were also noted

about the knees.

A spinal and mid-forceps delivery was necessary because of a

secondary arrest of labor.

A viable male child was delivered weighing

8 pounds, 5 ounces at 37 weeks gestation with an apgar score of 3/7.
anomalies were noted.

Blood loss during delivery was estimated at 1200

ml due to secondary uterine dystocia.
blood and plasmanate.

No

Treatment included two units of
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During the postpartura period hospitalIzation was extended because

of extreme lethargy, fevers, subcostal chest pain, a low hemoglobin, for
which she received more blood, and a high bacteria count in the urine.
Laboratory findings included a positive ANA and false-positive VDRL; ele

vated white blood count; negative LE cell test; 1.3 gm protein in a 2^-hour
urine test, and hemoglobin ranging from 7-6 to 8.3 gm. Her serum creati-

nine was normal, the reticulocyte count 12.5. At discharge she was feel ing
well, afebrile, and taking 20 mgprednisone daily. During the next three
raonths she felt well but had episodic joint pains and a pale maalar rash;

prednisone was reduced to 15 mg daily. Seven months after del ivery she
had a voluntary laparoscopic tubal sterilization.

Case C. This Mexican-American female was first diagnosed as

having SLE at the age of 15V reportedly because of swelling of her knee

and ankle and a false-positive VDRL.

No treatment was prescribed until

the age of 19, when she became pregnant, developed pneumonia, and was

hospitalized for gross pulmonary hemorrhages. This hospitalization was

complicated by a traeheostomy and a gastrectomy. Laboratory data at the
time included false-positive VDRL, hemolytic anemia. Coombs positive,
elevated sedimentation rate, ANA and complement within normal l imits. She

also had nephritis requiring dialysis for a time and underwent a kidney
biopsy which showed diffuse proliferative glomerulonephritis.
By the age of 26 she became pregnant for the seventh time. Her

reproductive history prior to this current pregnancy had included one

full-term child, given away for adoption; one spontaneous abortion; three
therapeutic abortions performed in anticipation of exacerbation, which
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occurreei anyway; and one premature del ivery, stil 1 born.

She had a strong

desire to have a child, so with this seventh pregnancy medical help was

not sought until after the fifth period was missed and abortion was out
of the guest ion.

Throughout the pregnancy she remained on 17.5 mg of

predn i sone daily, pi us Choledyl, Actlfed, and vitamins.

She had had a

history of proteinuria, 1 ess than one gram per 2k hours, ever since her
hospitalization at age 19. This proteinuria continued throughout the
pregnancy with Some untreated, mild hypertension.

During the third tri

mester the creatine clearance dropped from 80 ml per minute to 50 ml per
minute, while the serum blood urea nitrogen and creatinine remained nor
mal.

She was hospitalized at this time to assess renal function and

because a B-scan showed the chiId to be 32 to 33 weeks gestation, al
though by dates it was 39 weeks.

reported at 84 ml per minute.

A repeat creatinine clearance was

The following day she spontaneous]y went

into labor and delivered a viable male child weighing 3 pounds, 15

ounces with an apgar of 7/9 and no anomalies.

During labor and immedi

ately postpartura her blood pressure was elevated, 140/100 to 130/120, and
treated with Apresoline.

During 1abor she was also given 50 mg of Solu-

cortef in addition to her regular daily dose of 17.5 mg of prednIsone.

Laboratory results during delivery included false-positive VDRL, negative
ANA, complement 3 normal, total complement and complement 4 below norma1.
The day following del i very she had a voluntary tubal 1i gat ion.

Three days 1ater she was discharged on 17.5 mg of prednisone daily.
Throughout pregnancy and delivery she had no clinical symptoms of disease
activity aside from the laboratory data already mentioned.
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The fourth day after discharge she began having manifestations
of disease activity including fever and chills; malaise; unawareness of
her surroundings; paroxysms of cough, which became progressively worse

and caused dehisence of the incisibnal wound; vomiting; joint paint#
'

.

•

was readmi tted 12 days after the previous discharge.

She

i

Laboratory data at

this time included false-positive VDRL, negative ANA, hemoglobin 7-^ gm.

Coombs positive (2+ direct); Westergren sedimentation rate 146; anergy to
skin tests; complement 3 normal. Treatment included 40 mg of Soluroedrol

and 45 to 60 mg of prednisone daily. She remained in the hospital only
five days, leaving prematurely because there was no one to look after her

child.

At discharge a low-grade temperature and cough continued.

was discharged on 40 mg of prednisone.

She

No follow-up visit is recorded.

Case D. At age 24 this Mexican-American female was diagnosed as
having SLE with initial major symptoms involving Raynaud's phenomenon of
the hands.

Symptoms were successfully treated with corticosteroids and

dibenzyline regimen.

Two years later, one month after the birth of her

fifth child, she was rehospitalized with fever, migratory arthralgias,
night sweats, subcostal chest pain, and anterior chest pain.

Laboratory

results at the time showed leukopenia, false-positive VORL, and negative
LE cell and ANA tests. The next year the Raynaud's phenomenon progressed,
necessitating a right and left cervical sympathectomy.

At the age of 29 she became pregnant for the sixth time.

Repro

ductive history included four full-term del iveries and one spontaneous

abortion. During pregnancy no corticosteroids were taken, only iron and
vitamins. She was asymptomatic until approximately two weeks prior to
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delivery, when she complained of chest pain and the hemoglobin dropped
to 10.3v

39 weeks gestation she delivered a 6 pound, 7 ounce female

with an apgar of 7/8. First-stage labor was complicated by meconium
stain. Two days following delivery she had an elective tubal l igation.
Hemoglobin remained low, 9.2, at discharge.

No other symptoms were noted.

An isolated clinical entry one year later stated that Raynaud's
had progressed, involving the legs bilaterally. She was limited to

walking only two blocks before severe pain occurred. Laboratory data
included a positive ANA test, a negative LE cell, and positive rheumatoid
factor 1:10.

Case E. This 26-year-old Mexican American had one prenatal visit,
at approximately five months gestation, prior to delivery of a viable

4-pound, 4i-ounce female with an apgar of 7/9. Estimated date of concep
tion was unknown, buj: the child was considered premature.

Disease activity dated back nine years, when diagnosis of rheuma

toid arthritis had been made and treatment of sal icylates and gold therapy
instituted. Approximately one year prior to pregnancy she had an acute

flare of disease activity, was hospitalized, and diagnosed as having SLE.
Major clinical symptoms included neuropathy and rayopathy.

Medi

cations taken during pregnancy included 25 mg of prednisone twice daily,

Dilantin, vitamins, and iron.

On the delivery day and first postpartum

day the dosage of prednisone was increased to 80 mg, then reduced to 40
mg at discharge.

Laboratory results at the time of delivery included

normal complement 3, ANA, VORL, and hemoglobin.

hospitalization she remained asymptomatic.
available.

During the three-day

No follow-up record was

Ik

Case F.

For this Caucasian feraale diagnosis of SLE was made at

age 14 with initial symptoms including butterfly rash, edema associated
w

ith renal disease, and blood tests (records not available).

She had

had no prescribed treatment and had remained asymptomatic except for a
butterfly-rash.

She became pregnant for the first time at age 20. Prior to deli

very she had one^prenatal visit at approximately two months gestation.
At an estimated

to 6 months gestation she began feeling tired with pro

gressive weakness and dizziness, plus shortness of breath on exertion.
This progressed over several weeks until after she had suffered with

fevers to 104° and alterations in consciousness her family had her adm

itted to the hospital.

One week prior to admission was the last time

she reported fetal motion. On admission the laboratory tests yielded
the following results: hemoglobin 4 gms; positive Coombs test, both

direct and indirect measurements; false-positive VDRL; and positive ANA
and LE cell. She was transfused with six units of packed red blood cells

and begun on Decadron, totaling 24 mg in 24 hours, and thereafter 60 mg of
prednisone daily. She improved symptomatically but signed out of the
hospital against medical advice because of financial problems.

readmitted at another institution.

She was

By dates she was approximately 31

weeks gestation but only 18 weeks by size. After three days she spon
taneously del ivered a macerated male fetus with no external malformations

but with extensive placental infarction.

Two days prior to delivery the prednisone was discontinued.

Laboratory data at the second institution included negative Coombs and
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ANA tests, and a false-positive VDRL.

The day following delivery she

was asymptomatic and therefore diseharged.

No further record was avail

able.

A summary of fetal outcome is presented in Table 3-

A summary

of the number of exacerbations occurring during the first, second, and
third trimesters is presented in Table h.

In Case F the determination

of the occurrence of exacerbations is questionable since this patient,

was reported to be 31 weeks by gestation but only 18 weeks by size.
Table 5 summarizes the number of exacerbations occurring in the prepregnancy, pregnancy, and postpartum periods.

In Case B it is assumed

the exacerbation occurred prior to delivery and continued into the post
partum.

Case Studies of Nonpregnant Group

Case G.
as having SLE.

At the age of 23 this Black female was first diagnosed
initial manifestations included fever, precordial chest

pain, myalgia, arthralgia, fatigue, anorexia with weight loss.

Labora

tory data showed a marked elevation in the sedimentation rate, a negative
VDRL, a positive ANA, no LE cells in three samples, hypergammaglobul inemia,

rheumatoid factor 1:640, 24-hour urine protein of 520 mg.
treated with salicylates, 12 tablets daily.

Symptoms were

After discharge the joint

pains continued and some dyspnea was noted on exertion.

Thirteen days

after discharge she was readmitted with high fever and chest pain that
was worse on inspiration and lying down.

Chest x-ray showed an enlarging

heart and mi 1d diffuse infiltrates on the lungs bilaterally.
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was 7.7 gra, sedimentation rate was 59. She was started on 60 mg of
prednisone daily with rapid improvement of symptoms.
Clinical records were available for the next seven months.

During this time she was asymptomatic except for an occasional report
of chest pain; prednisGne was slowly tapered to 10 mg every other day.
For the next three years she received medical care at another institu

tion, receiving varying dosages of prednisone and being admitted to a
hospital once for pancreatitis.

On return to the cl inic she reported taking 5 mg of prednisone
every One or two weeks, depending on her symptoms.

At this time all

prednisone was discontinued. During the next 15 months she experienced
episodes of chest pain which were partially controHed by Ascriptin. At
the end of this time she was admitted again for chest pain, fever, and
arthralgias.

Antinuclear antibody was

at 1:16 dilution, sedimentation

rate kS, total complement low; echocardiogram showed no evidence of peri
carditis. The treatment included 500 mg and 250 mg of Solu-medrol

followed by 60 mg of prednisone daily, tapered to kO mg daily at dis
charge, and Arthropan.

Chest pain waxed and waned during the next several months, with

prednisone dosage ranging from 10 to A5 mg daily.

Six months after the

last discharge she was admitted again with arthralgia, fatigue, alopecia,
pruritic macular rash, and subcostal and precordial chest pain.

Treat

ment consisted of 80 mg of prednisone tapered to 40 rag at discharge plus
Arthropan. Two weeks after discharge she was readmitted with changes in
mentation and incoherent speech. Temperature was 103°F, axi11ary; the
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sedimentation rate, 66; blood urea nitrogen, 40; urinalysis granular and

hyaline casts; no urine output since admission. She was given 1 gm of
Solumedrol for three consecu.tive days. On the third hospital day she
developed a respiratory arrest and was intubated; a cardiac arrest fol
lowed and she expired.
/

Case H.

.

.

.

At age 27 this Caucasian fema1e first had symptoms of

SiE v./ith intermittent arthralgias, fever, fatigue and anemia.

Six months

later she was hospital ized for joint pains, fever and night sweats; a
diagnosis of SLE was made. Laboratory results at the time yielded the
following results:

positive ANA and LE eel 1, rheumatoid factor 1 :1280,

low serum complement, hypergammaglubulinemia, sl ightly elevated blood

urea nitrogen, creatinine clearance 53 ml per minute; leukopenia; and

24-hour urine protein 60 mg. it was felt she most likely had focal pro1iferative nephritis, not nephrotic. Treatment consisted of 40 mg of
prednisone daily and Persistin, which rapidly rel ieved her symptoms.
Several weeks after discharge, while continuing to take 40 mg of

prednisone daily, she began having a recurrence of symptoms, so the
prednisone was inereased to 80 mg every other day. The first day off
the medication she became confused, weak, and febrile, and complained of
leg pains. She was readmitted approximately one month after the previous

discharge. During hospitaiization she had a spiking of temperature to

103.8°F; pleuritic chest pain; spontaneous pneumothorax, chest tube
placement; macular hemorrhage in the left eye, sealed with laser beam;

oral ulcers; a paranoid reaction with depression; staph aureus coagulase
positive septicemia; hemolytic anemia. Treatment included prednisone in
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various dosages up to 100 mg daily and then decreased progressively to
30 mg daily at discharge.

One month after discharge she was readmltted for incision and
drainage of an abscess in the buttocks from previous injection sites.

She is an eleroentary school teacher and taught full time the next year.
Clinical records during the next eight months state that she was doing
well with 15 to 20 mg of prednisone daily, with only occasional Joint
pains.

Nine months after the last hospital ization for exacerbation she

was readmitted with complaints of nausea, fever, night sweats, back and
1 eg pains.

She was found to have a urinary tract infection; ANA and LE

cell were positive.

The fourth day of hospitalization she signed out

against medical advice on 30 mg of prednisone daily and promptly re
turned to work despite fever and urinary tract infection.

One month

after leaving the hospital she was readmitted with fever, arthralgia,

intermittent pleuritic pains. Symptoms were.treated with large doses
of steroids up to 200 mg daily and tapered to 20 mg daily at discharge.

Also 50 mg of Cytoxan daily was initiated. The ANA remained positive,
creatinine clearance varied from 52 ml per minute to 87 ml per minute,
LE cell was negative, and blood cultures positive for staph aureus
coagulase.

No further records were available.

Case I.

At the age of 20, this Mexican-American female was

diagnosed as having SLE, primarily because of an erythematous rash,
arthralgias, fever, and a positive ANA.

During the next year she worked

in a factory until she developed a rash involving the face, chest, and
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abdomen, which was treated with 60 mg of prednisone daily. Three months
later she was admitted to a hospital with a deterioration in mental

status, violent behavior, disorientatlon, joint pains, headache, dizzi

ness, and continued rash. The prednisone was reduced to 15-20 mg to

rule out steroid psychosis. At this time all neurological testing was
normal, but the sedimentation rate was elevated.

Mentation gradually

cleared on 15 mg of prednisone daily. Steroid challenge acGentuated her
psychosis, so it was felt to be primary in nature.

She was transferred

to a psychiatric unit, where she was stabil ized on Haldol and Cogentin.

Depression continued. She was discharged two months later on 15 mg of
prednisone every other day.
C1 inic records over the. next year-and-a-half show she was stable

on 20 to 30 mg of prednisone taken every other day. The ANA remained

positive, complement low, sedimentation rate elevated. Episodic joint
pains and nervousness continued. She was unable to do her regular work
but did volunteer work.

Case J. This Mexican-American female had a history of seizures

beginning at age 10. From 15 to age 21 she had no seizures, the epi
sodes being well controlled on Mysoline.

At age 21 she began having

joint pains, fever, fatigue, diffuse hair loss, and malaise.

These

symptoms persisted, and six months later she was hospitalized.

Clinical

manifestations included blurred vision, which by history developed over

the last two months, andwas iritermittent in nature; diplopia; mild head
aches; shingles. Pertinent laboratory data included anti-DNA 12.8;

positive ANA; sedimentation rate markedly elevated; urinalysis normal;
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negative VDRL; anergy to skin tests; Greatinine clearance 90 ml per roinute.
Renal biopsy showed lupus nephritis, focal in nature, with membranes

spared.

Ophthalmologic tests showed optic atrophy secondary to SLE be-'

cause of the following symptoms:

papilledema, visual fields consistent

with i ncreased blind spot. Intermittent exotropia, mild proptosis.

She

was treated with Decadron for several days and then 120 mg of prednisone

which was decreased to 80 mg daily at discharge.
During the next two months headaches, fever, blurred vision and

tiredness Continued.

She was readmitted because of a seizure, chest

pain, and flashing black and yellow 1 ights in her eyes.

Chest x-ray

showed a smal1 pleural effusion and an ultrasonic cardiogram, a small to

raoderate pericardial effusion. Prednisone was increased to 120 mg for
four days and then decreased to 80 mg dally. Dilantin and phenobarbi tal
were also initiated.

During the next two months she improved although

joint pains and rash continued; prednisone was reduced to 50 mg daily.
She was briefly readmitted after two months for gastroenteritis.
After discharge her condition improved with a subsequent reduction in
prednisone. Three months 1ater while vacationing, her anticonvulsant
medications were changed.

One month later, after returning home, she

was admi tted with unGontrolled seizures. She was given a 100 mg dose of

prednisone, which was tapered to 40 mg at discharge. Antinuclear anti
body rema i ned positive, creat in ine clearance normal.

Clinic records for

the next two years showed disease act ivi ty fai rly stable with occasional
joint pains or rash. The major problem had been her loss of vision,
which progressed unti1 she is now legally bl ind.

She does not work.

Prednisone is maintained at 30 mg every other day.
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Case K. At age 17 this Caucasian female was diagnosed as having
SLE on the has is of a skin rash and joint pains.

Treatment included 15

mg of prednisone daily, which she continued for eight years.

At 25 she was hospitalized for six days with fever and chest pain
that increased on inspiration. During this time an ANA test was positive;
VORL negative; creatinine clearance normal; sedimentation rate sl ightly
elevated. Treatment included 40 mg of Solu~medrol for three days, then

40 mg of prednisone daily. One month and a half after discharge she was
readmitted with chest pain and hemoptysis. Chest x-ray and bronchoscopy
at the time were normal. Treatment included 20 mg of prednisone daily.
During the next eight months, cl inic records state, she was

feeling well except for a stasis uTcer of the left leg and a relentless
skin rash' She was Once again hospitalized after eight months because

of progression of the skin rash, mouth ulcers, chest pain, arthralgia,
and night sweats. Antinuclear antibody r^ained positive, serum creati
nine negative. Symptoms improved on 50 mg of prednisone, although the
rash persisted.

Skin rashes continued during the next six months despite varying
dosages of prednisone. She worked at two different jobs during this
time. At the end of this six months she was hospitalized for three days
with chest pains and a chronic productive cough. Two months later she

was again briefly hospital ized with a skin rash, fever, pleuritic pain,
and joint pains.

Chest x-ray at this time was. normal and ANA remained

pos i t i ve.

Clinical records for the following year showed continued problems
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with reeurring skin rash, and productive cough.

Prednisone dosage varied

from 20 to 60 mg daily.

Case L.

At age 21 this Black fetnale first had symptoms of SLE

with a skin lesion on her Idft cheek which was biopsied and diagnosed as

1upus. The l esion increased in s ize, and a generalized mildly pruritic
rash occurred on both cheeks, forehead, dorsum of nose, arms, shoulders,

and Tegs.

The following year a kidney biopsy was performed which showed

membranoproliferative diffuse glomerulonephritis.

She was diagnosed as

having SLE and started on 60 mg of prednisone daily, which was progres
sively tapered to zero over the next year.

She appeared to have a fairly

stable course throughout the next two years without any use of steroids.
At the end of th is time she had a flare of disease act ivi ty and was

hospitalized with a rash, loss of hai r, arthralgias, high fevers, maiaise,
weight loss, cough, and edema of the eyelids.

A chest x-ray showed an

enlarged heart and congestive heart failure with b ilateral pleural effu
sions.

Her course was complicated by two episodes of ventricular

fibrillation, which was corrected by cardioversion and cardiac drugs.

Laboratory data produced the following results:

sedimentation rate

markedly elevated, negative VDRL, 1.9 gm protein in a 24-hour urine test,
creatinine clearance 52 ml per minute, positive ANA, norma1 anti-DNA,

hypergammaglobulinemia.

Dosages of prednisone during hospital ization

ranged from 60 to 160 mg daily.

Clinic notes after discharge showed

gradual resolution of the pleural effusions and rash throughout the next
month with a subsequent tapering of the prednisone to 30 mg daily.
Over the next seven months the patient had no symptoms, with
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urina1ysis normal, sedimentation rate dropping, creatinine clearance

normal, the ANA remaining positive. Prednisone was slowly tapered to
12.5 mg da i1y.

Discussion

An exacerbation, as previously defined, is an increase of disease

activity by one or more grades.

A summary of disease activity over a

period of time for the pregnant group and nonpregnant group is presented
in Figures 1 and 2.

These figures represent disease activity only for

the length of time that documented medical records existed in each sur

veyed case, not for the past history which was also often available but

without documentation.

For exemple, the figure representing one week for

Patient F is only for the actual medical document available, even though
several weeks' history was also described in the record.

Because of the

brief medical records with resultant difficulty in grading disease acti
vity or deterraining when cl inical changes occurred, these figures are

only estimates and should not be used as absolute representation of
disease activity.

They are given as a general summary of the case

studies and should not be used in comparing the two groups.
Findings of the comparative study of the above case records indi

cate possible answers to the following questions:

Question 1. What effect will pregnancy have in precipitating
exacerbation of disease activity in SLE. women when they are compared with

a similar group of SLE women not experiencing pregnancy?

In a comparison

of the number of exacerbations per group according to length of record.
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the rionpregnant group had more exacerbations over a period of time.
higher rate of exacerbation could be related to several factors.

This

First,

it should be noted that none of the nonpregnant group reached Grade 0 of
disease activity, while two patients in the pregnant group were at this
asymptomatic level.

One questions if the two groups were equally matched

according to disease activity.

Failure to match could possibly be due to

vague criteria for grading disease activity.

Second, the only reason why

the nonpregnant subjects were selected for the study was that they hap

pened to be-hospitalized because they were undergoing exacerbation of the
disease.

In comparison, only one of the pregnant group was admitted

during a period of exacerbation.

The rest were selected because they

were pregnant and had SLE, but there was no correlation with exacerba
tion.

A third factor was the length of medical record available per

patient.

In the pregnant group all but one medical record covered a

time of less than 10 months whereas every case but one of the nonpregnant
group covered at least one year and two months.

These data may be pointing to the fact that pregnancy does not

always precipitate an exacerbation of disease activity, particularly in
a we 11-control led, stable prepregnaney state.

Although four out of the

eight pregnancies were associated with exacerbation, the small sample

size makes the data inconclusive and general ization impossible.
Question 2.

Is there a difference in the occurrence of exacerba

tions of SLE during the first, second, and third trimesters of pregnancy?
The results showed no exacerbation during the first or second trimester

and two exacerbations during the third trimester.

Both of these

,
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exaGerbations occurred very close, within one month, to the time of

delivery.

In the reviewed literature Fraga, Zurier, and Estes similarly

reported no exacerbations during the first trimester although all re
ported exacerbations during the second trimester (Fraga, and Others,

1074; Zurier, and Others, 1978; Estes and Larson, I965).
Question 3.

Is there a difference in the occurrence of exacer

bations during the prepnegnancy, pregnancy, and the poStpartum periods
of the SLE patient? The results showed exacerbation occurred equally
between pregnancy and postpartura.

Of four exacerbations, two occurred

during the postpartum, two during pregnancy, and none during prepregnancy-

All exacerbations occurred close to the time of delivery, two

within one week of delivery and two within six weeks.

It is difficult

to general ize about these three periods, especially the postpartum,

because of the short 1ength of medical records available after del ivery.
Three case records ended wi thin days of delivery.
The above data suggest exacerbation of disease activity occurs
close to the time of del ivery.

Can this activation be related to an

antigenic stimulus from fetal antigens occurring at or near the time of

delivery? Can it possibiy be due to a sudden suppression of 17-hydroxycorticosteroids at the termination of pregnancy? These questions must
be answered by future research.

Chapter 5

SUMHARY, CONCLUSION, AND RECOMMINDATIONS

Sumwary

System!c lupus erythematosus (SLE) oecurs most frequently in women
during the reproductive years.

A review of the literature raised some

question about the safety of pregnancy for women in this age group.

It

showed that exacerbation is a frequent occurrence postpartum and also re

ported a large nuitiber of cases where initial onset of SLE occurred duri ng
pregnancy.

The conclusions reported in the literature, however, are sub

ject to question for three reasons:

no distinction was made in earlier

studies between discoid lupus and SLE, no control groups were used, and
the samp1ing was smail.

This descriptive case study used raedical records of six pregnant
and six nonpregnant women with SLE.

It was initiated to investigate the

effect pregnancy would have in precipitating exacerbate on of the disease

activity when compared with those in a similar nonpregnant group.

The

difference In occurrence of exacerbation between the three trimesters of

pregnancy and the prepregnancy, pregnancy, and postpartum period was also
stud led.

It was theorized that the reported increase in exacerbation could

be related to a new antigenie stimulus provided in the form of fetal

antigens to an already imbalanced maternal immune system.

The mixing of

fetal and maternal blood at the time of delivery, it was surmised, could
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provide the mechanism for an outpouring of such antigens.

A second

thedry was related to the abrupt suppression of l7*hydroxyGorticosteroids

at the termination of pregnancy, with a withdrawal of a possibly strong
immunosuppressive mechanism active during pregnancy.

In a comparison of the number of exacerbations per group according
to length of record, the nonpregnant group had more exacerbations.

In the

pregnant group, the only exacerbations occurred during the third tri-

roester.

In the prepregnancy, pregnancy, and postpartum periods there

were two exacerbations in the postpartum period, two during pregnancy,
and none during prepregnancy.

Conclus ions

When a group of six pregnant women with SLE were compared with a
similar group of nonpregnant SLE women, the occurrence of exacerbation

was higher in the nonpregnant group.

This may point to the fact that

pregnancy does not always precipitate an exacerbation of disease activity.

But because of the l imitations of uncontrolled variables, low sample size,

difficulty in matching disease activity and 1ength of time since original
diagnosis, and imbalance in length of hospital records, generalization

of this finding is imposs ible.

it does i11uminate the prob1 ems of the

study des ign and provide feedback for needed changes which will be dis
cussed in the section on recommendations.

During the eight pregnancies reported, exacerbations occurred

only during the third trimester, close to the time of delivery.

It was

also found that of the prepregnancy, pregnancy, and postpartum periods,
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two exaGerbations occurred duririg postpartuffl, two during pregnancy, and
none during prepregnanGy.

These data suggest that If pregnancy is under

taken by women with SLE the risk of exacerbation might be greatest during

the third trimester and postpartura.

The sample size of the present study,

however, is too smal1 to make such a generalization.

This informatibn would be helpful to the nurse in two respects.
First, she could inform a questioning SLI woman that exacerbation of
disease activity during pregnancy is not always the rule and that if

exacerbation should occur, the limited data indicate it would most l ikely
be during the third trimester, possibly close to the time of del ivery, or

postpartum.

Secondly, the nurse caring for the pregnant or postpartum

SLE woman could be cognizant that such minor complaints as joint pains,
sore muscles, mouth ulcers, slight chest pain on inspiration, or unex
plained low fever could possibly be heralding the onset of exacerbation.

Recommendat ions

In the future if a study similar to this is initiated it is sug

gested that instead of grading disease activity by the number of manifes
tations present, activity could be judged solely according to limitation.

The following is a suggestive scale:
Grade 0:

No limitation of activity, work or school

Grade T:

Partial limitation, possibly working

Grade 2:

Limi tat ion of activity, no work

Grade j:

Hospital ization

Also, continued contact with patients past the hospital setting and over.
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a longer period of time would prdvide more cbmplete data about the
various pregnancy pjeriods.

As a further means to illuminate the relationship of SLE to the
two theoretieal bases for exacerbation, the following hypotheses are

1.

increasing parity in the SLE woman will have no significant

(a=».OS) effect on the number of exacerbations occurring during the preg
nancy and postpartum periods.

2. There will be no significant (a=.05) difference between the

time of del ivery and exacerbation when a group of primiparous SLE women
are compared to a similar group of multiparous SLE women.
3.

During the monthly raenstrual cycle of an SLE woman there will

be no significartt (a=.05) difference in clinical symptoms of disease
act i V i ty duri ng the t i me of menstrual flow or three days prior when com
pared with the fifteenth day of the cycle.

h. A prospective compari son of pregnant SLE patients wil l yield
no consistent Gharacteristics or factors present in those who do compared
with those who do not have exacerbations.
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April 27, 1979

5,3

Mrs. Marilynn Opincar, R.R.A.
Director of Medical Records

Loma Linda University Medical Center
Loma Linda, CA 92373
Dear Mrs. Opinear;

As a graduate student in nursing, I am investigating the effects
of pregnancy on systexnic lupus erytheixiatosus. This study is to
meet part of the requirements for a master's degree in nursing
at Loma Linda University. I am hereby requesting permission to
include medical records from Loma Linda University in my^study.^

My committee chairman, Evelyn L. Elwell, has approved this thesis
and I will obtain approval from the University Committee on H^xman
Studies.

The proposed research is a matched case contol study of retro

spective design utilizing medical records. Medical records will
be reviev/ed from the years 1968-1978 and all patients who meet

the sample criteria will be included®

Data will be extracted

from the records utilizing a data extraction checklist for each

patient. All data will be collected under a code momber by a
single researcher, ilames with assigned code numbers will oe
kept on a separate listing to be destroyed.

With your permission I would like to begin data collection during
the first week in May. I expect to collect data on at least eignt

patients in a period of three to four weeks, I will be happy to

make an appointment with you to discuss this research further
if you desire. Space has been provided on the attached letter
from the Graduate Program for your reply. Thank you for your
assistance.

Sincerely,

Julia Christensen, R.N., B.S.

Graduate Program in Nursing
Loma Linda University
School of Nursing
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CONSENT FORM

As a graduate student in nursing and as part of

the requirements for a master's degree in nursing, I am
investigating the effects of pregnancy on systemic lupus

erythematosus,

Medical records will be examined primarily

to ascertain the possibility of pregnancy causing exacer
bation of disease activity,
I am hereby requesting permission to include

Loma Linda University's medical records in this study, i^rhich
is explained in more detail below.

Patients will not be

contacted or asked to sign a -consent form.
Criteria For Sample Selection

1.

Female.

\

2»

Age 16 through

3,

Systemic lupus erythematosus diagnosed according

to ARA criteria,

R.,

Documented history of pregnancy past the ''6-week

gestation (group A, required of Ll patients).

No history of pregnancy (group B, required of
I4. patients).
6,

Diagnosis of lupus prior to pregnancy.
Procedure

Medical records will be revieiN^ed from the years

-2-

.
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1968-1978 and ell palients who meel the semole criteria

for group A will be.included in the sample.

The records

will then be surveyed for all x\fho meet the criteria for

group B, Group B will then be matched to group A. Data
will be extracted from the records utilizing a data extrac-'

tion checklist for each patient.

All data will be collected

under a code number by a single researcher.

Names with

assigned code numbers will be kept on a separate listing

to be destroyed.

Risk for the patient either physicallyj

emotionally, or socially is minimal, only occurring through
a breach of confidentiality, which will be carefully guarded^

Graduate Student

GUI

an

^ominittee Chairman

' Date

Date

-------6.ZI'i.

-

APPENDIX B

LETTER FROM ETHICS IN STUDENT RESEARCH COHMITTEE
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LOMA LINDA UNIVERSITY

Loma Linda Campus
LOMA LINDA, CALIFORNIA 92350
La Sierra Campus
RIVERSIDE, CALIFORNIA 92515

SCHOOL OF NURSING

Approval Data

Julia Cliristensen

854 Pine Avenue, Apt B
ledlanda, CA 92373

Dear Graduate Student:

The Ethics in Student ResearGh Committee has reviewed the proposal you
submitted for a researGh study to partially fulfill the School of Nursing

requirements for a iHaster of Science degree from Loma Linda University.
The Committee has voted that your study is:

Approved as submitted in the specified setting for one year.

Approved in the specified setting for one year after the recom
mended changes have been made and a memo from your research
chairman

to this effect has been received by the committee

chairman.

Not approved as submitted to the committee. ■ See the attached
comments for reGommended changes.
any data collection.
^

X

Deferred to:

X

UCOHS

Must be resubmitted prior to
Research Chairman

Other

Please see attached recommendations and/or comments regarding
this action.

Please remember to give all signed consent forms to the Research Coordin
ator.

Please contact the Chairman of the Ethics in Student Research

Corrniittee if you have questions related to the decision of the Committee.

If any changes are made in the hypothesis, tool, consent form, or the
procedure for data collection, this proposal must be resubmitted to this
Committee. If data collection extends beyond one year the proposal must
be resubmitted to the Committee.

We pray that the Lord will continue to bless your endeavors.
Sincerely,
o-

Evelyn L. Elwell, Chairman
Ethics in Student Research Committee

xc: Research Committee Chairman _ Evelyn Elwell

^3

RECOMMENDATIONS AND/OR COMMENTS

Get consent from Mr. Ruffcorn or his office for permission to review
charts.

Comments:

Is this study justifiable as a nursing study?

APPENDIX C

ADVISOR APPROVAL OF RESEARCH PROPOSAL SUBMITTED TO

THE UNIVERSITY COMMITTEE ON HUMAN STUDIES
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ADVISOR APPROVAL OF RESEARCH PROPOSAL SUBMITTED TO THE
UNIVERSITY COMMITTEE ON HUMAN STUDIES

To;

Dr. Gordon Rick

^ Chairsiaiij University Connnittee
on Human Studies

From:
Subject;

Evelyn L. Elwell

^ Resear'^^ Advisor

Research proposal approval for submission to the University
Committee on Htman Studies

Oraduate Student's (Investigator's) Name;

Date;

5/2/79

Option; Thesis ^

Julia Christensen

Non-thesis

Pub. Paper

The proposed research of this graduate student is of suffi-

cient X , more than sufficient

, excellent

scientific merit for ful

fillment of the requirements for graduate study.

I have approved its sub^

mission to the University Committee on Human Studies as it is outlined in
the attached condensed research proposal.

In my opinion» the extent of

the emotional, physicali and social risk to the persons to be included in

the proposed sample is non-existent X , minimal
(please explain).

moderate

, other

The proposed research is expected to contribute to the

human welfare, is within the capability of the student and is feasible to

carry out within a reasonable time.

Thank you.

Signature of the Research Advisor

This study was deferred to Human Studies because it is a retrospective
chart review for which the student is not obtaining patient consent.
Most of patients are deceased and this study is epidemiological in nature.
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Loma Linda Campus
LOMA LINDA, CALIFORNIA 92350

La Sierra Campus
RIVERSIDE, CALIFORNIA 92515
GRANTS RESOURCES SERVICE

May \k, 1979

Julia Chrtstensen

c/o Dr. Evelyn Elwel1
School of Nursing
Loma Linda University
Dear Ms. Christensen:

Your proposal for a study entitled "The effect of pregnancy oh systemic lupus
erythematosus" was reviewed by the Committee on Human Studies of Loma Linda
University at its regular meeting May 9> 1979.
The act ions of the commi ttee are as fo11ows:
The subjects are not at risk.

The protocol is approved.

if there a re mod i f i ca t i ons to the proposed research protocol or consent form,
or problems arising from the study, please notify the committee in writing of
these changes or problems.

if you have questions, p1 ease feel free to contact

us.

You will be asked to provide a progress report on this study in six months, or
at the conclusion of this study.
Best wishes in your project.
Sincerely yours,

Li nda G. Hal stead

Secretary
Committee on Human Studies

LGH:ag
Enc
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AMSRICAN RHEUmTISM ASSOCIATION PRELIMINARY
CRITERIA FOR CLASSIFICATION OF SLE

A patient is said to have SLE if any four or more
of the following

manifestations are present either serial

ly or simultaneously.

1.

Facial erythema (butterfly rash)

2.

Discoid lupus

3-

Raynaud's phenomenon

4. Alopecia
5*

Photosensitivity

6.

Oral or nasopharyngeal ulceration

7«

Arthritis without defortiity

8.

LE cells

9.

Chronic false-positive STS

10. Proteinuria of greater than 3'5 g/day
11.

Cellular casts

12.

One or both of the following:

(a) pleuritis,

(b) pericarditis

13*

One or both of the following:

(a) psychosis,

(b) convulsions

l4. One or more of the following; (a) hemolytic
anemia, (b) leukopenia, (c) thrombocytopenia (Bulmash, 1978,
p. 171).
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DATA eXTRAGTiON CHECKLIST
Patient I dent ifieation Data

Caucasian
Code Number
Date of
IMP;

DOB

Race:

Hispanic

American Indian

Asian

Black

Other

Outcome of previous pregnancies:
Para:

Date of

pelivefy:

Gravida:

Type of
Deli very;

Fetal
Outcome;

Viable

Stillborn

Maternal
Demi se:

ARA

1.
2.

3.
k.

Criteria for Diagnosis
Erythematosus rash
Discoid lupus
Alopecia
Photosens i t i vi ty

Cause of Death:

8.

9.

5.
6.

0ra 1/nasa 1 u 1 ce rs

7.

Arthri ti s/no deformi ty 10.

Raynaud's Phenomenon

Serosal inflammation

a.
b.
CNS
a.

pleuritis
pericardi t i s
changes
psychos i s

IT.

False positive

12.

Proteinuria

13.

Cellular Casts

STS

(3.5 gm)

b. convulsions
False Positive STS

1^.

Hematologic
a. Anemia

b. Leukopenia

OTHER:

c. Thrombocyto
ASS RACTED DATA:
Post
Pre
Partum
6
3rd
dn2om.
Tri
Ist
Pregnancy

fosnsnotiabtarecseafxiEnaM

T3
t.

'o
«
OC

rehtO
Brief Narrative Summary:

